(Q33733451)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

0 references

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

16

Kathy Miller

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Roni Mamluk

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Irvith M Carvajal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Brent A Morse

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Henry Wong

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Janette Abramowitz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Sharon Aslanian

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Ai-Ching Lim

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jochem Gokemeijer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Michael J Storek

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Joonsoo Lee

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Michael Gosselin

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Martin C Wright

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Ray T Camphausen

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jack Wang

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Yan Chen

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Kerry Sanders

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Sarah Short

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jeff Sperinde

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Gargi Prasad

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Stephen Williams

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Robert Kerbel

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Anthony Mutsaers

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

John D Mendlein

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Alan S Harris

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Eric S Furfine

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 March 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

published in

Monoclonal Antibodies

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

199-208

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

Engineered protein scaffolds as next-generation antibody therapeutics.

19 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

VEGFR3: a new target for antiangiogenesis therapy?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Targeting angiogenesis in renal cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

VEGF: an essential mediator of both angiogenesis and endochondral ossification

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Tumor angiogenesis and accessibility: role of vascular endothelial growth factor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Directed evolution of high-affinity antibody mimics using mRNA display

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Therapeutic monoclonal antibodies: trends in development and approval in the US.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Size-exclusion chromatography--multiangle laser light scattering analysis of beta-lactoglobulin and bovine serum albumin in aqueous solution with added salt

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Vascular endothelial growth factor (VEGF) and its receptors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

The fibronectin type III domain as a scaffold for novel binding proteins

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules

21 June 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.2.11304

Correlations between in vitro potency of polyethylene glycol-protein conjugates and their chromatographic behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.2.11304

Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.2.11304

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.2.11304

Vascular Endothelial Growth Factor-C A Growth Factor for Lymphatic and Blood Vascular Endothelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.2.11304

Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840239

Neutralizing effects of an anti-vascular endothelial growth factor antibody on tooth movement

30 October 2018

1 reference

12 December 2020

Using Biacore to measure the binding kinetics of an antibody-antigen interaction

1 reference

12 December 2020

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

12 December 2020

Vascular endothelial growth factors C and D represent novel prognostic markers in colorectal carcinoma using quantitative image analysis

1 reference

12 December 2020

Vascular endothelial growth factors and receptors in colorectal cancer: Implications for anti-angiogenic therapy

1 reference

12 December 2020

Localization of human colorectal tumor xenografts in the nude mouse with the use of radiolabeled monoclonal antibody

1 reference

12 December 2020

Identifiers

DOI

10.4161/MABS.2.2.11304

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

release_yeegelmxfne5dn5ngivjjd7hsq

19 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yeegelmxfne5dn5ngivjjd7hsq

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20190562%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

PubMed publication ID

20190562

1 reference